Prestige Consumer Healthcare (PBH) Other Non-Current Liabilities (2013 - 2026)
Prestige Consumer Healthcare (PBH) posted quarterly Other Non-Current Liabilities of $5.7 million for Q4 2025, up 14.28% year-over-year from $5.0 million in Q4 2024, and up 6.84% quarter-over-quarter from $5.4 million in Q3 2025.
Prestige Consumer Healthcare (PBH) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Prestige Consumer Healthcare's Other Non-Current Liabilities history runs 13 years deep, the most recent figure standing at $5.7 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities rose 14.28% year-over-year to $5.7 million; the TTM figure through Dec 2025 stood at $5.7 million (up 14.28% YoY), while the FY2025 annual figure was $5.4 million, down 41.31% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $5.7 million, up from $5.4 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $9.2 million in Q1 2024, with the low at $5.0 million in Q4 2024.
- The 5-year median for Other Non-Current Liabilities is $8.3 million (2021), against an average of $7.4 million.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Liabilities sank 66.15% in 2021, then increased 14.28% in 2025.
- Prestige Consumer Healthcare's Other Non-Current Liabilities stood at $8.4 million in 2021, then increased by 5.21% to $8.9 million in 2022, then increased by 0.53% to $8.9 million in 2023, then slumped by 43.61% to $5.0 million in 2024, then climbed by 14.28% to $5.7 million in 2025.
- Business Quant data shows PBH's Other Non-Current Liabilities at $5.7 million in Q4 2025, $5.4 million in Q3 2025, and $5.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Prestige Consumer Healthcare | 2.43 Bn | 2.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.58 Mn |
| Dec 31, 2025 | 5.75 Mn |
| Sep 30, 2025 | 5.38 Mn |
| Jun 30, 2025 | 5.41 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 5.12 Mn |
| Jun 30, 2024 | 5.14 Mn |
| Mar 31, 2024 | 9.19 Mn |
| Dec 31, 2023 | 8.92 Mn |
| Sep 30, 2023 | 8.90 Mn |
| Jun 30, 2023 | 8.18 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 8.87 Mn |
| Sep 30, 2022 | 8.88 Mn |
| Jun 30, 2022 | 8.92 Mn |
| Mar 31, 2022 | 7.48 Mn |
| Dec 31, 2021 | 8.43 Mn |
| Sep 30, 2021 | 8.49 Mn |
| Jun 30, 2021 | 8.56 Mn |